A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.

A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.

We report a cisplatin and irinotecan combination in patients with biopsy-proven advanced pancreatic adenocarcinoma. Patients were selected from a specialist centre and required good performance status (KPS>70%), measurable disease on CT scan, and biochemical and haematological parameters with...

Full description

Bibliographic Details
Main Authors:	Markham, C, Stocken, D, Hassan, A
Format:	Journal article
Language:	English
Published:	2003

Similar Items

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
by: Rea, D, et al.
Published: (2005)

A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage Treatment in Refractory or Relapsed Small Cell Lung Cancer
by: Shufei YU, et al.
Published: (2013-09-01)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
by: Tej Tummala, et al.
Published: (2023-10-01)

Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer
by: Ritsuko eKomaki, et al.
Published: (2011-12-01)

Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2018-11-01)

Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
by: Xichao Dai, et al.
Published: (2023-08-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
by: Ke Cheng MD, PhD, et al.
Published: (2022-02-01)

Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review
by: Nan YAO, et al.
Published: (2009-08-01)

Capecitabine/irinotecan combination regimens in colorectal cancer.
by: Kerr, D
Published: (2002)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
by: Jun Gong, et al.
Published: (2022-09-01)

Modelling prognostic factors in advanced pancreatic cancer.
by: Stocken, D, et al.
Published: (2008)

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
by: Francesca Simionato, et al.
Published: (2020-09-01)

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles
by: Valencia, Pedro M, et al.
Published: (2015)

Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer
by: Yu-Hsuan Liu, et al.
Published: (2023-01-01)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
by: Ryoji Takada, et al.
Published: (2023-07-01)

Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
by: FNU Asad ur Rahman, et al.
Published: (2017-07-01)

The effective combination therapies with irinotecan for colorectal cancer
by: Yun Chai, et al.
Published: (2024-02-01)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
by: Amol Gupta, et al.
Published: (2023-08-01)

A phase II trial of marimastat in advanced pancreatic cancer.
by: Evans, J, et al.
Published: (2001)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
by: Liuting Yang, et al.
Published: (2018-04-01)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
by: Middleton, G, et al.
Published: (2013)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
by: Middleton, G, et al.
Published: (2013)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
by: Therese Bocklage, et al.
Published: (2013-04-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
by: Jun Gong, et al.
Published: (2022-11-01)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
by: Sandrine Barbier, et al.
Published: (2023-01-01)

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
by: Kenneth H. Yu, et al.
Published: (2023-04-01)

PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
by: M. Hoseinzadeh Mollayosefy, et al.
Published: (2006-06-01)

PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
by: M. Hoseinzadeh Mollayosefy, et al.
Published: (2006-04-01)

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
by: Sabharwal, A, et al.
Published: (2010)

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer
by: Yutaka Ogata, et al.
Published: (2013-02-01)

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer
Published: (2013-01-01)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
by: Koji Kikuchi, et al.
Published: (2022-10-01)

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101
by: Yosuke Kawashima, et al.
Published: (2023-09-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
by: Pui Lam Yip, et al.
Published: (2023-04-01)

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
by: Xiangsheng Liu, et al.
Published: (2021-03-01)